|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
20.06.25 - 12:21
|
Ipsen receives positive CHMP opinion for Cabometyx® in previously treated advanced neuroendocrine tumors (GlobeNewswire EN)
|
|
|
PARIS, FRANCE, 20 June 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for Cabometyx® (cabozantinib) for adult patients with unresectable or metastatic, well differentiated extra-pancreatic (epNET) and pancreatic (pNET) neuroendocrine tumors who have progressed following at least one prior systemic therapy other than somatostatin analogues. This recommendation is based on results from the CABINET Phase III trial presented at the European Society of Medical Oncology (ESMO) Congress 2024 and published in the New England Journal of Medicine.3,4 A final decision on the approval in the European Union is expected in the coming months....
|
|
|
|
|
|
|
|
|
|
|
02.06.25 - 23:42
|
XFRA: DIVIDEND/INTEREST INFORMATION - 04.06.2025 - EQUBF_01 (XETRA)
|
|
|
Das Instrument I7G FR0010259150 IPSEN S.A. PORT. EO 1 EQUITY wird cum Dividende/Zinsen gehandelt am 03.06.2025 und ex Dividende/Zinsen am 04.06.2025
The instrument I7G FR0010259150 IPSEN S.A. PORT. EO 1 EQUITY has its pre-dividend/interest day on 03.06.2025 and its ex-dividend/interest day on 04.06.2025...
|
|
|
|
|
|
|
|
|
|
|
|
|
06.05.25 - 07:33
|
Ipsen appoints Laura Réveillon as EVP, Strategy & Transformation (GlobeNewswire EN)
|
|
|
PARIS, FRANCE, 06 May 2025 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care-driven biopharmaceutical company, announced today the appointment of Laura Réveillon, PhD as EVP, Strategy & Transformation, effective May 14, 2025. She will serve on the Executive Leadership Team and report directly to Ipsen's Chief Executive Officer (CEO), David Loew....
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
